RSV disease--is there a role for prevention?
W
W
Lenney
D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000191:economics / Q000627:therapeutic use; D001249:Asthma / Q000209:etiology; D002648:Child; D002675:Child, Preschool; D003362:Cost-Benefit Analysis; D006801:Humans; D007116:Immunization, Passive / Q000379:methods*; D007223:Infant; D007231:Infant, Newborn; D008173:Lung Diseases, Obstructive / Q000209:etiology; D000069455:Palivizumab; D018579:Patient Selection; D018357:Respiratory Syncytial Virus Infections / Q000150:complications / Q000517:prevention & control*; D022261:Respiratory Syncytial Virus Vaccines / Q000191:economics / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D022261:Respiratory Syncytial Virus Vaccines; D000069455:Palivizumab